Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xB3-NOX4 small interfering RNA
- Development stage
- Preclinical
- Lead developer
- Bioasis Technologies
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
xB3-NOX4 small interfering RNA is a preclinical research compound developed by Bioasis Technologies. It utilizes the company's proprietary xB3 platform, which is based on a modified version of melanotransferrin (p97), to facilitate the transport of a small interfering RNA (siRNA) payload across the blood-brain barrier (BBB). The siRNA specifically targets NOX4 (NADPH oxidase 4), a gene associated with the production of reactive oxygen species and oxidative stress, which are key drivers of neuronal damage in ischemic stroke. By knocking down NOX4 expression in the central nervous system, the drug aims to reduce neuroinflammation and infarct size.
- Other names
- xB3-NOX4 small interfering RNAxB-3-NOX4 small interfering RNAxB 3-NOX4 small interfering RNAxB3-siRNA (NOX4)
02
Targets
NOX4 (NADPH oxidase 4)
Beyond the preview
Go deeper on xB3-NOX4 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xB3-NOX4 small interfering RNA.